How to Get Praluent (Alirocumab) in Mississippi

What Is Alirocumab and Why Is It Prescribed?

Alirocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces the liver's ability to clear LDL cholesterol from the bloodstream. By blocking PCSK9, alirocumab allows more LDL receptors to remain active on hepatocyte surfaces, pulling LDL-C out of circulation at a faster rate.

The FDA approved Praluent in 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond maximally tolerated statin therapy (FDA label). In ODYSSEY OUTCOMES (N=18,924), alirocumab 75 mg or 150 mg every two weeks reduced the composite endpoint of coronary heart disease death, nonfatal myocardial infarction, ischemic stroke, or unstable angina requiring hospitalization by 15% compared with placebo (HR 0.85; 95% CI, 0.78 to 0.93; P<0.001) over a median follow-up of 2.8 years [1]. Patients whose baseline LDL-C was 100 mg/dL or higher saw the greatest absolute benefit.

Mississippi ranks among the top five states for cardiovascular mortality, according to CDC data from 2023 (CDC heart disease statistics). That epidemiologic burden makes PCSK9 inhibitor access a pressing clinical question for Mississippi providers and patients alike.

Who Can Prescribe Praluent in Mississippi?

Any Mississippi-licensed prescriber with authority to prescribe legend drugs can write a Praluent prescription. That includes physicians (MD and DO), nurse practitioners (NPs), and physician assistants (PAs). Mississippi grants NPs full practice authority after completing a supervised collaborative practice period, meaning NPs practicing independently can prescribe Praluent without a collaborating physician's co-signature.

Cardiologists and lipid specialists write the majority of PCSK9 inhibitor prescriptions nationally, but primary care physicians, endocrinologists, and internists also prescribe alirocumab when patients meet clinical criteria. The prescriber's specialty matters less than the documentation they submit for prior authorization. Payers want to see objective evidence of statin failure or intolerance, not a specific specialty credential.

For patients in rural Mississippi counties without nearby lipid specialists, telehealth removes a geographic barrier that previously required hours of travel for a single consultation. A telehealth prescriber licensed in Mississippi can evaluate labs, review medication history, and submit the prior authorization electronically.

Telehealth Access to Praluent in Mississippi

Mississippi permits telehealth prescribing of prescription medications, including PCSK9 inhibitors, under the state's telemedicine regulations. A provider must hold an active Mississippi medical license (or be registered through an interstate compact) to prescribe to patients located in the state.

A typical telehealth visit for Praluent follows this sequence. The patient uploads recent lipid panel results and a medication history showing prior statin therapy. The provider reviews the data during a synchronous video consultation, confirms the diagnosis (HeFH or ASCVD), and submits the prescription along with the prior authorization packet. Most telehealth platforms partner with specialty pharmacies that handle the prior authorization process on behalf of the provider.

The American Heart Association's 2018 cholesterol guideline recommends adding a PCSK9 inhibitor for patients with clinical ASCVD at very high risk whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe therapy (AHA/ACC 2018 guideline) [2]. Dr. Seth Martin, a preventive cardiologist at Johns Hopkins, has noted: "PCSK9 inhibitors fill a gap for patients who cannot reach LDL goals with oral therapy alone. Telehealth has made it possible for patients in underserved areas to access these medications without a three-hour drive to an academic center."

Telehealth visits typically cost between $50 and $150 out of pocket when insurance does not cover the consultation. Some platforms accept commercial insurance or Medicare for the visit itself, billing separately from the medication cost.

Required Labs Before Starting Praluent

Before prescribing alirocumab, clinicians order a standard set of baseline laboratories. These labs serve two purposes: confirming the clinical indication and satisfying payer prior authorization requirements.

Fasting lipid panel. This is the most important test. The panel reports total cholesterol, LDL-C, HDL-C, and triglycerides. Payers typically require an LDL-C value drawn while the patient is on maximally tolerated statin therapy (or after a documented statin intolerance trial). An LDL-C at or above 70 mg/dL for ASCVD patients, or at or above 100 mg/dL for HeFH patients without ASCVD, is the common threshold for PCSK9 inhibitor approval.

Hepatic function panel. Baseline ALT and AST help rule out active liver disease, which could complicate lipid-lowering therapy interpretation.

Creatine kinase (CK). If the patient reports prior statin-related myalgia, a CK level documents whether there was objective muscle injury versus subjective intolerance. Some payers request this as part of the statin intolerance documentation.

HbA1c or fasting glucose. Because PCSK9 inhibitors have been studied for potential glucose effects, some clinicians check baseline glycemic status, although alirocumab has not shown clinically significant diabetes risk in trial data. In the ODYSSEY OUTCOMES trial, new-onset diabetes rates were similar between alirocumab and placebo groups [1].

Labs drawn within the prior 90 days are generally accepted by insurance companies. Patients using telehealth can have labs drawn at any Quest, Labcorp, or hospital-affiliated laboratory in Mississippi before their virtual appointment.

Prior Authorization in Mississippi: Step-by-Step

Prior authorization is the single largest barrier to Praluent access in any state, and Mississippi is no exception. Nearly every commercial insurer, Medicare Part D plan, and pharmacy benefit manager (PBM) requires prior authorization for PCSK9 inhibitors.

Step 1: Document statin history. The prescriber must show that the patient has tried at least two statins at the highest tolerated dose, or has a documented contraindication to statins. Some plans also require a trial of ezetimibe, either alone or in combination with a statin.

Step 2: Submit the LDL-C value on current therapy. This lab result proves that the patient has not achieved guideline-recommended LDL-C targets despite oral lipid-lowering therapy. The 2018 AHA/ACC guideline defines "very high risk" ASCVD patients as those with a history of multiple major ASCVD events or one major event plus multiple high-risk conditions [2].

Step 3: Confirm diagnosis. The payer requires ICD-10 codes supporting HeFH (E78.01) or ASCVD (I25.10 for coronary artery disease, I63.9 for ischemic stroke, or similar). For HeFH, some plans accept the Dutch Lipid Clinic Network score or Simon Broome criteria as diagnostic evidence.

Step 4: Submit the PA form. Most PBMs use CoverMyMeds or a proprietary portal. The form asks for the patient's diagnosis, statin trial history, current LDL-C, and the requested alirocumab dose (75 mg or 150 mg every 2 weeks). Turnaround time ranges from 24 hours to 14 business days. If denied, the prescriber can file a peer-to-peer appeal.

A 2019 analysis published in JAMA Cardiology found that prior authorization requirements for PCSK9 inhibitors were associated with a 49.7% abandonment rate, meaning nearly half of patients for whom a PCSK9 inhibitor was prescribed never filled the medication (JAMA Cardiology, 2019) [3]. Mississippi patients face the same friction.

Mississippi Medicaid Does Not Cover Praluent

Mississippi's Medicaid program does not include alirocumab on its preferred drug list. This coverage gap affects a significant portion of the state's population: Mississippi has one of the highest Medicaid enrollment rates in the country, with approximately 780,000 enrollees as of 2024 (CMS Medicaid enrollment data).

Patients on Mississippi Medicaid who need a PCSK9 inhibitor have limited options. Some may qualify for Regeneron's MyPraluent Copay Card program, though manufacturer copay cards generally cannot be used with government insurance programs (Medicaid, Medicare, Tricare). Regeneron does offer a separate patient assistance program for uninsured or underinsured patients that may apply in certain cases.

Patients dually eligible for Medicare and Medicaid may have PCSK9 inhibitor coverage through their Medicare Part D plan, subject to Part D prior authorization requirements. Checking both benefit structures is a step that prescribers in Mississippi should not skip.

Commercial Insurance and Medicare Part D Coverage

Most commercial plans in Mississippi cover Praluent as a non-preferred specialty tier drug after prior authorization. Out-of-pocket costs vary widely. With manufacturer copay assistance, commercially insured patients may pay as little as $0 per month. Without copay assistance, specialty tier copays can range from $150 to $500 per month depending on the plan's benefit design.

Medicare Part D plans cover Praluent under specialty tier (Tier 5) with prior authorization. The coverage gap ("donut hole") phase can expose patients to 25% coinsurance on a drug with a list price near $450 per injection. Once the patient reaches catastrophic coverage ($8,000 true out-of-pocket for 2025), coinsurance drops to 5%.

The Inflation Reduction Act's $2,000 annual out-of-pocket cap for Part D, fully effective in 2025, means Medicare patients on Praluent will not pay more than $2,000 per year in total Part D drug costs regardless of how many fills they need (CMS Part D redesign).

Specialty Pharmacies and 503A Compounding in Mississippi

Praluent is classified as a specialty medication and is dispensed primarily through specialty pharmacies. Major specialty pharmacy networks operating in Mississippi include CVS Specialty, Accredo (Express Scripts), and AllianceRx Walgreens Prime. These pharmacies handle cold-chain shipping (alirocumab must be refrigerated at 2 to 8 degrees Celsius), patient education on self-injection technique, and ongoing refill coordination.

Mississippi does license 503A compounding pharmacies under the state Board of Pharmacy. However, alirocumab is a biologic (a monoclonal antibody) that cannot be compounded by a 503A pharmacy. Biologics require specialized manufacturing processes governed by the FDA's biologics license application (BLA) pathway. No 503A or 503B compounder produces alirocumab. Patients must obtain the brand-name Praluent manufactured by Regeneron/Sanofi.

There is no FDA-approved biosimilar for alirocumab as of May 2026, although biosimilar development programs are underway. Until a biosimilar receives approval, Praluent remains the only alirocumab product on the market.

Patients in Mississippi can receive Praluent via mail-order specialty pharmacy with next-day cold-chain shipping to any address in the state. Rural patients who lack proximity to a brick-and-mortar specialty pharmacy are not disadvantaged by geography for this particular medication.

How Long Until You Receive Praluent in Mississippi?

The timeline from initial provider visit to first injection varies based on insurance type and prior authorization speed. A realistic breakdown follows.

Days 1 to 3. Lab results return (if not already on file). The provider submits the prescription and prior authorization.

Days 3 to 10. The PBM reviews the prior authorization. Straightforward approvals (clear ASCVD diagnosis, documented statin failure, LDL-C above threshold) often come back in 48 to 72 hours. Complex cases or cases requiring additional documentation can take 7 to 14 business days.

Days 10 to 14. Once approved, the specialty pharmacy contacts the patient to schedule delivery, verify the shipping address, and confirm someone will be home to receive the temperature-sensitive package.

Total: approximately 2 to 3 weeks for most patients with commercial insurance or Medicare Part D. Patients facing a denial and appeal can wait 4 to 8 weeks. Self-pay patients who bypass prior authorization can receive the medication within 3 to 5 business days of prescription submission.

Transferring a Praluent Prescription to Mississippi

Patients relocating to Mississippi from another state can transfer an active Praluent prescription. The process depends on the pharmacy type. Specialty pharmacies operating in multiple states (CVS Specialty, Accredo) can often transfer the prescription internally without requiring a new order from a Mississippi-licensed provider.

If the patient's out-of-state provider is not licensed in Mississippi, a new Mississippi-licensed prescriber must issue a prescription. The prior authorization may also need to be resubmitted if the patient changes insurance plans during the move. Keeping copies of previous PA approval letters, lab results, and medication history speeds this process considerably.

Mississippi recognizes prescriptions written by providers licensed in other states for a limited fill (typically one 30-day supply) under emergency or transitional circumstances, but ongoing PCSK9 inhibitor therapy requires establishment with a Mississippi-licensed clinician.

Monitoring While on Praluent

After starting alirocumab, follow-up labs are straightforward. The 2018 AHA/ACC guideline recommends rechecking a fasting lipid panel 4 to 12 weeks after initiation to assess LDL-C response [2]. Alirocumab 75 mg every 2 weeks typically reduces LDL-C by 45% to 50% from baseline. If the response is insufficient, the dose can be uptitrated to 150 mg every 2 weeks or switched to the 300 mg monthly pen.

Injection-site reactions are the most commonly reported adverse effect, occurring in 7.2% of alirocumab-treated patients versus 5.1% on placebo in the ODYSSEY OUTCOMES trial [1]. Serious adverse events were comparable between groups. No routine hepatic or renal monitoring is required beyond what the patient's underlying conditions dictate.

Patients should report muscle symptoms if they arise, though PCSK9 inhibitors do not share the myotoxicity mechanism of statins. Neurocognitive effects were studied in the ODYSSEY OUTCOMES neurocognitive substudy, which found no significant difference in cognitive outcomes between alirocumab and placebo groups, even among patients who achieved LDL-C levels below 25 mg/dL (NEJM 2017, EBBINGHAUS substudy) [4].